Suchergebnisse - "Vanella, Vito"

PubPharm (6)

1

Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma

enthalten in: Expert opinion on emerging drugs | 2021

von Vanella, V. | Festino, L. | Vitale, M. | +2

2

Impact of COVID-19 outbreak on cancer immunotherapy in Italy : a survey of young oncologists

enthalten in: Journal for immunotherapy of cancer | 2020

von Ottaviano, M. | Curvietto, M. | Rescigno, P. | +93

3

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors : A multicentre analysis of immune-related adverse events

enthalten in: European journal of cancer (Oxford, England : 1990) | 2020

von Cortellini, A. | Bersanelli, M. | Santini, D. | +35

4

The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era

enthalten in: Current oncology reports | 2019

von Vanella, V. | Festino, L. | Trojaniello, C. | +4

5

Selecting immuno-oncology-based drug combinations - what should we be considering?

enthalten in: Expert review of clinical pharmacology | 2018

von Festino, L. | Vanella, V. | Trojaniello, C. | +1

6

Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase : a case report from a phase III trial

enthalten in: Cancer immunology, immunotherapy : CII | 2016

von Ascierto, P. | Vanella, V. | Grimaldi, A. | +4

1
[1]